Literature DB >> 4006735

Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL.

D L Howrie, R J Ptachcinski, B P Griffith, R J Hardesty, J T Rosenthal, G J Burckart, R Venkataramanan.   

Abstract

Acute anaphylactoid reactions occurred immediately after initiation of intravenous infusions of cyclosporine in three patients post-organ transplantation. Shortness of breath, flushing, tachypnea, chest pain, pruritus, or urticaria were noted; rapid recovery followed cessation of drug infusion. Subsequently, oral cyclosporine has been used in each patient without recurrence of the observed reaction. The presence of Cremophor EL as an emulsifying agent in the parenteral dosage formulation of cyclosporine is a likely etiology for this acute adverse reaction. Slowed rates of drug infusion and antihistamine premedication may permit continued intravenous cyclosporine use in affected patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006735     DOI: 10.1177/106002808501900603

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  16 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Ditosylate salt of itraconazole and dissolution enhancement using cyclodextrins.

Authors:  Neeraj Kumar; Gulshan Bansal; Sandeep Kumar; Asim Kumar Jana
Journal:  AAPS PharmSciTech       Date:  2012-06-06       Impact factor: 3.246

3.  Acute effects of cyclosporin and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat heart.

Authors:  P Mankad; J Spatenka; Z Slavik; G O'Neil; A Chester; M Yacoub
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 4.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 5.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells.

Authors:  Mira F Francis; Mariana Cristea; Yali Yang; Françoise M Winnik
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

7.  Residue mass plot and abundance plot: detection of isobaric interferences in DE-MALDI-TOF-mass spectra of complex polymer mixtures.

Authors:  T Meyer; M Kunkel; A W Frahm; D Waidelich
Journal:  J Am Soc Mass Spectrom       Date:  2001-08       Impact factor: 3.109

Review 8.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

9.  Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.

Authors:  M E Dolan; A E Pegg; R C Moschel; B R Vishnuvajjala; K P Flora; M R Grever; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Efficacy evaluation of a novel submicron miconazole emulsion in a murine cryptococcosis model.

Authors:  M Y Levy; I Polacheck; Y Barenholz; S Benita
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.